Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC

Rhea-AI Summary

Beckman Coulter unveils the DxI 9000 Access Immunoassay Analyzer, a clinical diagnostics tool that addresses laboratory demands for speed, reliability, reproducibility, quality, and menu expansion. The analyzer has the capability to develop sensitive and clinically relevant assays, providing new opportunities to quantify trace amounts of biomarkers in blood samples. The collaboration with Fujirebio will support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in neurodegenerative diseases. The DxI 9000 also excels in improving clinical laboratory operations with zero daily maintenance requirements and automated safeguards to prevent erroneous reporting.

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer, addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion. The DxI 9000 Analyzer has shown capability to develop increasingly sensitive and clinically relevant assays enabling the platform to keep pace with tomorrow's testing requirements as healthcare providers and pharmaceutical companies take aim at evermore challenging diseases. 

We believe that there is more clinical data available from a patient's blood sample than is currently accessible.

According to Zivjena Vucetic, M.D., Ph.D., Chief Medical Officer and Senior Vice President, Medical & Scientific Affairs, President, Beckman Coulter Diagnostics, "We believe that there is more clinical data available from a patient's blood sample than is currently accessible. Early system evaluations and conversations with users suggest that the DxI 9000 Analyzer opens up new opportunities to quantify trace amounts of key biomarkers in blood samples. The implications extend throughout healthcare systems. For example, in Alzheimer's disease, adding a highly accurate and more patient-friendly testing option to current diagnostic solutions, with the goal of providing alternative options to PET-imaging or a lumbar puncture, amplifies the impact of new pharmaceutical therapies and ultimately improves patient outcomes."

Ray Divilley, Chief Medical Officer, Mayo University Hospital, Ireland, was an early evaluator of the DxI 9000 Analyzer added, "With the DxI 9000, Beckman Coulter has successfully produced a platform that addresses today's laboratories needs for speed, accuracy, and reliability. Based on our use and evaluation of the system in our lab, we were able to get actionable results back quicker to doctors and ultimately patients as they consider treatment options." 

Recently, Beckman Coulter Diagnostics and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases. Initial assay development efforts will focus on the recently introduced DxI 9000 Access Immunoassay Analyzer and the widespread installed base of Access Family Immunoassay Analyzers.

"This collaboration with Beckman Coulter will help accelerate the deployment of our portfolio of new, novel neurodegenerative biomarkers to laboratories and clinicians around the world. As the pre-eminent provider of leading-edge immunoassays to the diagnostics industry, this partnership is an important step to speed the transition of these markers from research to clinical use in all major geographies and to bring a higher standard of care to patients and their families in the battle against this debilitating disease," stated Goki Ishikawa, President & CEO, Fujirebio Holdings, Inc.

In addition to advancing diagnostics capabilities, the DxI 9000 excels in improving clinical laboratory operations.

ZeroDaily Maintenance highlights the embedded innovations that drive the DxI 9000 Analyzer's uptime performance. Beta users attest to ZeroDaily Maintenance redefining their workday with no daily maintenance requirements, thereby reducing annual maintenance routines by up to 96%.   

Building on Beckman Coulter's workflow and automation leadership, PrecisionVision Technology is unmatched in its ability to inspect, identify and prevent erroneous reporting in real time. PrecisionVision automated safeguards include tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check reduces the risk of reporting flawed data and increases system reliability and reproducibility.

The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.

Additional Resources

• Link to DxI 9000 Access Immunoassay Analyzer media kit
• Follow and connect with Beckman Coulter Diagnostics via LinkedIn, Twitter, and Facebook.

About Beckman Coulter. Inc.
A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Beckman Coulter is part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies. Headquartered in Brea, Calif., it has more than 11,000 global team members.

©2023 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2023-11982

View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulters-dxi-9000-immunoassay-analyzer-with-increased-assay-development-sensitivity-makes-first-north-american-appearance-at-2023-aacc-301884651.html

SOURCE Beckman Coulter, Inc.

FAQ

What is the name of the company behind the DxI 9000 Access Immunoassay Analyzer?

The company behind the DxI 9000 Access Immunoassay Analyzer is Beckman Coulter.

What are the key features of the DxI 9000 Analyzer?

The key features of the DxI 9000 Analyzer include speed, reliability, reproducibility, quality, and menu expansion. It can develop sensitive and clinically relevant assays and quantify trace amounts of biomarkers in blood samples. It also has zero daily maintenance requirements and automated safeguards to prevent erroneous reporting.

What is the collaboration between Beckman Coulter and Fujirebio about?

The collaboration between Beckman Coulter and Fujirebio aims to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in neurodegenerative diseases.

What are the benefits of the DxI 9000 Analyzer in clinical laboratory operations?

The DxI 9000 Analyzer improves clinical laboratory operations by requiring zero daily maintenance and providing automated safeguards to prevent erroneous reporting.

Where is the DxI 9000 Access Immunoassay Analyzer available?

The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.